Roche Holding Sees Q3 Growth: Diagnostics Upswing, Pharma Boost, & Strategic Investments
Roche Holding reports strong Q3 growth, with pharma sales up X % driven by multiple sclerosis, hemophilia, and ophthalmic drugs, while diagnostics rise modestly. The company reaffirms full‑year guidance, tight cost controls, and strategic investment…
3 minutes to read
